Piper Sandler Starts Crescent Biopharma Inc (CBIO) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CBIO Hot Sheet
Price: $13.46 +3.06%
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Piper Sandler analyst Biren Amin initiates coverage on Crescent Biopharma Inc (NASDAQ: CBIO) with a Overweight rating.
For an analyst ratings summary and ratings history on Crescent Biopharma Inc click here. For more ratings news on Crescent Biopharma Inc click here.
Shares of Crescent Biopharma Inc closed at $11.27 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- William Blair Downgrades Fidelity National Information Services (FIS) to Market Perform
- Northland on SolarEdge (SEDG): 'Storage remains a bright spot for the Company'
- United Therapeutics Corp. (UTHR) PT Raised to $768 at BTIG
Create E-mail Alert Related Categories
New CoverageRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
